medRxiv preprint doi: https://doi.org/10.1101/2020.10.23.20218479; this version posted December 11, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

COVID -19: could green tea catechins reduce the risks?

Maksim Storozhuk

Bogomoletz Institute of Physiology, National Academy of Sciences of Ukraine, Kyiv, Ukraine

Corresponding author
Dr. M. Storozhuk
Bogomoletz Institute of Physiology, National Academy of Science of Ukraine
4 Bogomoletz Street
Kiev 01024
Ukraine
Tel.: +380 44 2562052
Fax: +380 44 2536458
e-mail: maksim@biph.kiev.ua

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

medRxiv preprint doi: https://doi.org/10.1101/2020.10.23.20218479; this version posted December 11, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Abstract

Objectives: Several lines of emerging pharmacological and epidemiological evidence imply that overall risks related to COVID-19 may be reduced by green tea catechins. Therefore, it may be expected that: (i) higher green tea consumption is associated with lower COVID-19 morbidity and/or mortality; (ii) countries with higher per/capita green tea consumption would be less affected by COVID-19. The aim of this study was to assess the second possibility.

Study design: This was a cross-sectional study.

Methods: Among countries with at least 3 million population (n=134), countries with relatively high (above 150 g) per/capita green tea consumption have been tentatively identified (n=21); (ii) normalized to population values of COVID-19 cases (morbidity) and deaths (mortality) for groups of countries with high and low per/capita green tea consumption were compared.

Results: Striking differences in COVID-19 morbidity (and mortality) between groups of countries with 'high' and 'low' green tea consumption. The differences were still observed after the adjustment for the onset of the disease. Besides, preliminary analysis using multiple linear regression approach suggests that the associations are present at the level of individual countries.

Conclusion: Evidence supporting the idea that green tea constituents could reduce overall risks related to COVID-19 has been obtained. The results are promising and are in line with emerging evidence from other studies including pharmacological ones. Nevertheless, because of limitations of this study the idea still should be considered as a hypothesis requiring further assessment.

medRxiv preprint doi: https://doi.org/10.1101/2020.10.23.20218479; this version posted December 11, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Introduction.

There is emerging evidence suggesting that green tea constituents, in particular catechins such as (-)-epigallocatechin (EGC), and (-)-epigallocatechin-3-gallate (EGCG) may be protective in regard of COVID-19. As briefly outlined below this could be due to (i) direct anti-viral activity and (ii) the influence on factors associated with COVID-19 severity and mortality.

Green tea catechins, are known to have anti-viral activity against several viruses [1-4] including viruses causing respiratory diseases [5, 6]. Recent target-based virtual ligand screening study suggests that at least one catechin (EGCG), is likely to target papain-like proteinase (PLpro), an indispensable enzyme in the process of coronavirus replication and infection of the host [7]. Inhibition of SARS-CoV-2 3CL-Protease by EGCG has been recently demonstrated in *vitro* [8].

Additionally, several factors associated with COVID-19 mortality are likely to be affected by green tea constituents. Indeed, there is evidence that green tea catechins: lower cholesterol levels [9, 10]; have anti-diabetic [11] and anti-obesity effects [12]; are beneficial in cardiovascular disease [13].

Besides, EGCG is protective in diseases with uncontrolled immune activation, thus, may ameliorate severity of COVID-19 [14] since the latter is related to overreaction of the immune system [15]. Finally, green tea catechins can act as ionophores for zinc ions, while the latter are considered as potentially beneficial in relation to COVID-19 [16, 17].

Altogether these results suggest that green tea catechins could reduce overall risks related to COVID-19. If so, it may be expected that countries with higher level of green tea consumption are less affected by COVID-19.

To address this hypothesis a *preliminary* ecological analysis was performed in this study. For this purpose: (i) among countries with at least 3 million population (n=134), countries with relatively high (above 150 g) per/capita green tea

medRxiv preprint doi: https://doi.org/10.1101/2020.10.23.20218479; this version posted December 11, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

consumption have been identified (n=21); (ii) normalized to population values of COVID-19 cases (morbidity) and deaths (mortality) for groups of countries with high and low per/capita green tea consumption were compared.

Methods

Ethics Statement. Ethical approval was not deemed necessary as this was an analysis of publicly available data.

Identification of countries with relatively high per/capita green tea consumption

It has been previously reported that higher per/capita green tea consumption is typical for some countries in Asia, North Africa and Middle East [18]. Values for several countries in Asia (China, Vietnam, Japan and Indonesia) have been reported [19]. There is also information regarding Taiwan, arbitrary considered as a green tea consuming in the framework of this work because of predominant consumption of the Paochong tea (oxidized by only (8-12%) and Oolong tea (semioxidised) [20]. (The value of green tea consumption in Taiwan, indicated in the Table 1 (750 g) was arbitrary estimated as equal to one half of that reported [21] for *total* tea consumption in this country.) The relevant and reliable information regarding green tea consumption in the other countries is scarce [22], it is not as trivial as it may seem to find it. Therefore, to estimate the values of per/capita green tea consumption in the other countries the following approach was used. It was assumed that the difference between annual green tea import and export in a particular country (except countries with considerable green tea production) is roughly equivalent to annual green tea consumption. Thus, the difference between import and export divided by population should give a reasonable estimate of per/capita consumption. Indeed, such an approach is used for estimation for countries that do not produce tea [22].

medRxiv preprint doi: https://doi.org/10.1101/2020.10.23.20218479; this version posted December 11, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

The information about green tea import and export for particular countries was obtained from Commodity Trade Statistics Database | United Nations Statistics Division database [23]. Since for some countries recent records are unavailable, to minimize time bias, it was arbitrary chosen to use values for year 2016 as a standard (still for a few countries older records in the database were used in this work).

Using reported values for China, Vietnam, Japan and Indonesia [19], an estimate for Taiwan and the approach mentioned above it has been found that per/capita green tea consumption is above 150 grams in twenty one countries. However, it is essential to note that the list (Table 1) is probably incomplete (see considerations below), because the approach used for the estimate has several limitations. Namely, it cannot be excluded that some countries with considerable green tea per/capita consumption have not been identified among those producing green tea (for instance, Myanmar, South Korea, Papua New Guinea). Additionally, some countries may have not been identified because of absence of the relevant records in the UN database (for instance, Tajikistan). Finally, the estimates may be biased by import/export operations not reflected in the UN database. This is especially likely for 'smaller' import/export operations and thus for less populated countries. For this reason detailed screening of the database was limited to countries with at least 3 million of population.

Data regarding COVID-19 morbidity and mortality

All data were obtained from open resources. Information on total number of cases and total number of deaths was obtained from 'Worldometers info. Coronavirus' [24]. (The information on Worldometer is based on official daily reports and is considered as a reliable (for instance, [25, 26]).

For some comparisons information about COVID-19 morbidity (defined as number of cases per million population) and mortality (defined as number of deaths per million population) for a specific date was directly obtained from [24]. For others,

medRxiv preprint doi: https://doi.org/10.1101/2020.10.23.20218479; this version posted December 11, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

considering that the onset of the disease was not simultaneous in different countries an adjustment for this factor was made as described below. Date when the total number of confirmed cases in a particular country became 50 (or more) was determined based on information provided in [24] and considered as a reference time point (referred further as the onset date). Then information about the total number of cases/deaths at a date six months after the onset date was obtained from [24] and normalized to population. These adjusted values were (also) used for comparisons. Six-month period after the onset date has been chosen as a compromise between longer period for analysis and a number of countries available for analysis (performed in November 2020). Since in some countries the onset occurred in June and even July (2020) some countries were excluded from a comparison of the *adjusted* values. Calculated values reported in the tables are (typically) rounded to integer, while values used for statistical comparisons were not rounded.

Statistical analysis

Since the variables of COVID-19 morbidity and COVID-19 mortality do not have a normal distribution [25], non–parametric statistic was primarily employed for the analysis as suggested in [25, 27]. Namely, Wilcoxon (Mann-Whitney U Test) for Unpaired Data and Spearman Rank Correlation were used for the analysis. On the hand, for multiple linear regression analysis, an approach similar to that previously reported [25] was used. In this analysis, morbidity and mortality per million of population were transformed to the common logarithm (log10) to adjust for normality of the distribution as suggested previously [25].

Factors, included in multiple linear regression analysis (beside green tea consumption) were: population density [28], percentage of population aged above 65 [29], percentage of urban population [30]. In a complementary analysis additional

medRxiv preprint doi: https://doi.org/10.1101/2020.10.23.20218479; this version posted December 11, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

variable, namely Human Developmental Index (HDI) based on access to health and education services and income [31] was added to the model.

'KyPlot' software was employed for statistical assessments.

Results

A tentative list of countries with relatively high (above 150 g) per/capita green tea consumption was created using the approach described in Methods by screening relevant information for countries and territories listed in [24] *and* population with at least three million (134 countries and territories). Among those 21 were identified as countries with 'high' (above 150 g) per/capita green tea consumption (**Table 1**).

Table 1 A tentative list of countries with 'high' (above 150 g per/capita) green tea consumption.

	Country	Per capita green tea consumption (g)	COVID-19 morbidity (per million population)	COVID-19 mortality (per million population)
1	Mauritania	3400	1703	35
2	Morocco	1780	8135	133
3	Taiwan	750	25	0.3
4	Afghanistan	720	1117	42
5	Mongolia	657	143	0
6	Japan	650	945	15
7	Mali	537	194	7
8	Uzbekistan	520	2099	18
9	Libya	450	10850	151
10	Vietnam	380	13	0.4
11	Senegal	344	935	19
12	Algeria	332	1576	50
13	China	320	60	3
14	Hong Kong	293	728	14
15	Tunisia	248	6887	206
16	Guinea	229	954	6
17	Niger	213	54	3
18	Burkina Faso	167	126	3
19	Indonesia	200	1728	56
20	UAE	196	15380	54
21	Denmark	183	11129	132
	World[1] (average)		10366	183

Per capita green tea consumption is a coarse estimate (see Methods for details). In relation to further analysis, information regarding COVID-19 morbidity and mortality is also provided. This information was retrieved from 'Worldometer' [24] as provided on November 18, 2020. World1 – refers to top 212 countries and territories (ranked by population) affected by COVID-19 according to information from 'Worldometer' [24] as provided on November 18, 2020.

medRxiv preprint doi: https://doi.org/10.1101/2020.10.23.20218479; this version posted December 11, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Among the other 113 countries: in 15 the overall annual balance between import and export of green tea was negative; for 12 countries no records were found in the UN database. Since information about *production* of green tea in countries with negative import/balance was not available, the group of these 113 countries was considered as a group with (i) low and (ii) undetermined consumption. Finally, a group of countries with the *estimated* consumption below 150 g was considered as a 'low-consuming' (n=86). Information about total number of COVID-19 cases (per one million population) and total number of COVID-19- death (per one million population) was obtained from 'Worldometer' [24] as provided on November 18, 2020 for the countries from the above mentioned three groups and summarized in **Table 2**.

Table 2

COVID-19 morbidity (per one million population) and mortality (per one million population) in relation to per/capita green tea consumption.

	Group 1 (countries with 'high' green tea consumption) N=21	Group 2 (countries with 'low' or undetermined green tea consumption) N=113	Group 3 (countries with 'low' green tea consumption) N=86	World[1]
COVID-19 morbidity	954 (143-2099)	6486** (677-16263)	10023** (900-20342)	5421
COVID-19 mortality	18 (3-54)	101** (10-309)	160 *** (18-389)	66

Values are: median and interquartile range (IQR). ** (P<0.01) and *** (P<0.001) denote significance level of difference as compared to Group 1 (Wilcoxon (Mann-Whitney U Test) for Unpaired Data). Raw data for individual countries are from 'Worldometer' [24] as provided on November 18, 2020. World1 – refers to top 212 countries and territories (ranked by population) affected by COVID-19 according to information from 'Worldometer' [24] as provided on November 18, 2020.

Both, COVID-19 morbidity and mortality were strikingly (several times) lower in the Group 1 as compared to Group 2 (and Group3). Besides, the differences were highly significant (**Table 2**).

medRxiv preprint doi: https://doi.org/10.1101/2020.10.23.20218479; this version posted December 11, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

These results support the hypothesis that green tea constituents could reduce overall risks related to COVID-19. On the other hand, this preliminary analysis has several limitations. In particular, the onset of the disease was not simultaneous in different countries. To adjust for this the approach described in Method section was used.

A summary for the adjusted values is shown in **Table 3**. Notice a reduction of 'N' in the groups as compared to Table 2. This is due to late onset of the disease in some of the countries (Values for four countries in Group 2 and two countries in Group 3 were not available at a time of analysis (November 23, 2020). Nevertheless there were still profound and statistically significant differences in COVID-19 morbidity and mortality between Group 1 and Group 2/Group 3 (**Table 3**).

Table 3

Adjusted for the onset COVID-19 morbidity (per one million population) and mortality (per one million population) in relation to per/capita green tea consumption.

	Group 1 (countries with 'high' green tea consumption) N=21	Group 2 (countries with 'low' or undetermined green tea consumption) N=109	Group 3 (countries with 'low' green tea consumption) N=84
COVID-19 morbidity	813 (127-1604)	2625 ** (559-6554)	3455*** (766-7332)
COVID-19 mortality	13 (5-37)	54 ** (10-212)	83 *** (17-243)

Values are: median, IQR. ** (P<0.01) and *** (P<0.001) denote significance level of difference as compared to Group 1 (Wilcoxon (Mann-Whitney U Test) for Unpaired Data). Values represent epidemic situation six month after the onset of the disease (see Methods for more details) for the countries with known values as of November 23, 2020.

To check for possible association between per capita green tea consumption and COVID-19 morbidity/mortality at the level of individual countries corresponding

medRxiv preprint doi: https://doi.org/10.1101/2020.10.23.20218479; this version posted December 11, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

correlation coefficients were calculated. Namely, Spearman Rank Correlation was used to calculate correlation coefficients between: (i) the *adjusted* for the onset value of morbidity (or mortality) and (ii) per capita green tea consumption in a particular country. Thus, the total number of countries considered in this analysis was 105.

No statistically significant correlation between green tea consumption and the morbidity was observed (Rho=-0.13; P=0.17), while there was a weak but significant correlation between estimated green tea consumption and the mortality (Rho=-0.2; P=0.036).

To further study potential associations linear regression analysis accounting for several potential confounders was used. In this analysis: (i) morbidity and mortality per million population were transformed to the common logarithm (log10) to adjust for normality of the distribution (as suggested earlier [25]); (ii) in addition to green tea consumption, factors, reported previously as important confounders were included. In regard of the latter: population density [32]; percentage of population aged above 65 [32] and percentage of urban population [25] were included. Mauritania was excluded from the linear regression analysis as the apparent outlier in terms of estimated green tea consumption. (Indeed, value of 3400 g/capita is much greater than Q3+1.5*IQR for the *group with high green tea consumption* (where Q3 is 3-rd quartile, IQR interquartile range), thus was considered as outlier according to Tukey's rule [33].) Additionally, since number of deaths (per million) in Mongolia and Cambodia were 0 (as of November 23, 2020) and could not be transformed to the logarithm, these countries were excluded from the analysis in regard of the *mortality*.

It has been found that there are: weak but statistically significant correlations between morbidity (and mortality) and green tea consumption; stronger correlations between morbidity (and mortality) and percentage of urban population. Plots for COVID-19 morbidity and mortality in relation to these two factors are shown in **Fig. 1**; additional details about results of the analysis are provided in Supplementary **Table S1 (A,B)**.

medRxiv preprint doi: https://doi.org/10.1101/2020.10.23.20218479; this version posted December 11, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.



Figure 1. Percentage of urban population and per capita green tea consumption are associated with COVID-19 morbidity and mortality.
COVID- 19 morbidity (**A**, **C**) and mortality (**B**, **D**) in relation to % of urban population (upper panel) and green tea consumption (lower panel). Morbidity and mortality values are adjusted for the onset of the disease (6-month after the onset). Countries with values available as of November 23, 2020 were included. Values of regression coefficient R and significance levels denoted were calculated using the *multiple* linear regression model, N –number of countries included in the analysis. See text for more details. On plots **C** and **D** empty circles represent values for the countries with 'high' green tea consumption; for some of those standard two letter country codes are provided (AF- Afghanistan; CN –China; JP –Japan; LY- Libya; MA - Morocco; ML –Mali; MN-Mongolia; TW- Taiwan; UZ - Uzbekistan).

Thus, it appears that COVID-19 morbidity and mortality are indeed associated with green tea consumption at the level of individual countries. Of note, these associations were still statistically significant when additional important [32] variable, namely

medRxiv preprint doi: https://doi.org/10.1101/2020.10.23.20218479; this version posted December 11, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Human Developmental Index (HDI) based on access to health and education services and income [31] was added to the model (see Supplementary **Table S2 (A,B)**)

Discussion

The main finding of this study is that higher green tea consumption is associated with lower COVID-19 morbidity/mortality at the level of ecological study. Indeed, there are striking differences in COVID-19 morbidity/mortality between groups of countries with 'high' and 'low' green tea consumption. The differences were still observed after the adjustment for the onset of the disease. Besides, preliminary analysis using multiple linear regression approach suggests that the associations are present at the level of individual countries. At this level, this is presumably the first evidence supporting the idea that green tea constituents may reduce the risks related to COVID-19. These results are in agreement with several lines of emerging evidence implying that green tea catechins may be effective in prevention/treatment of COVID-19 or amelioration of its severity [7-11, 14] (as outlined in the Introduction). Nevertheless, in the context of this study, it would be fair to mention that green catechins are not *the only* constituents of green tea. Other constituents may be also of importance for potential beneficial effects.

Limitations of the study and potential future directions. For most of the countries green tea consumption was estimated based on the annual balance between its import and export. Although this approach is used for coarse estimates [22], apparently, it has several limitations as outlined in Methods. Thus, the list of countries with 'high' green tea consumption should be considered as a tentative. It cannot be excluded that some countries with considerable green tea per/capita consumption have not been identified among those producing green tea (for instance, Myanmar, South Korea, Papua New Guinea). It would be of interest to obtain relevant information in regard of

medRxiv preprint doi: https://doi.org/10.1101/2020.10.23.20218479; this version posted December 11, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

these countries, include it in the analysis and check how this would affect associations considered in this work.

Other limitations include multiple factors that may differentially affect COVID-19 morbidity and mortality in distinct countries. For instance, the administrative strategies to prevent transmission; population density, percentage of urban population, percentage of older population; condition-specific mortality risks; TB infection and BCG vaccination [25, 27, 34]. Potential role of only some of these factors was assessed in this study. On the other hand, potential confounding factors included in the linear regression model in this study are, actually, the majority of those identified as *consistent* (and at the same time relatively independent) in relation to COVID-19 in previous studies [25, 32]. Additionally, it appears that there are *causal* relations between green tea consumption, and several condition-specific risks (such as risks of cardiovascular diseases [13], diabetes [11], etc). Therefore, inclusion of these risk factors in the regression model *as confounders* would be rather controversial because a confounding variable should be an independent factor for outcome of interest [35].

It is important to notice that results of any ecological study, taken alone, could only provide the information about a correlation rather than a causal relation. Thus, experimental studies are required to either confirm or reject the potential causal relation. Importantly, green tea catechins are considered as safe by FDA and already have been investigated in experimental studies in relation to some infections. Moreover, results of at least one *randomized placebo-controlled* study [36] strongly suggest that green tea catechins can protect against acute upper respiratory tract infections (thus, quite likely, infections induced by members of coronavirus family). Therefore, it may be expected that green tea catechins can also protect against the infection induced by SARS-CoV-2. If this is the case, it would have very important implications. Possible efficacy of green tea catechins in treatment of COVID-19 and amelioration of its severity should be also assessed in observational and experimental epidemiological studies as potentially very important.

medRxiv preprint doi: https://doi.org/10.1101/2020.10.23.20218479; this version posted December 11, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Conclusion.

Evidence supporting the idea that green tea constituents could reduce overall risks related to COVID-19 has been obtained. The results are promising and are in line with emerging evidence from other studies including pharmacological ones. Nevertheless, because of limitations of this study the idea still should be considered as a hypothesis requiring further assessment.

Author statements

Ethics Statement

Ethical approval was not deemed necessary as this was an analysis of publicly available data.

Funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Competing interests

None declared.

Acknowledgments

I would like express my gratitude to personnel of the open resources for creating excellent opportunities for research.

medRxiv preprint doi: https://doi.org/10.1101/2020.10.23.20218479; this version posted December 11, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Reference List

1. Xu J, Xu Z, Zheng W: **A Review of the Antiviral Role of Green Tea Catechins**. *Molecules.* 2017, **22**.

2. Mhatre S, Srivastava T, Naik S, Patravale V: **Antiviral activity of green tea and black tea polyphenols in prophylaxis and treatment of COVID-19: A review**. *Phytomedicine.* 2020,153286.

3. Ghrairi T, Jaraud S, Alves A, Fleury Y, El SA, Chouchani C: **New Insights into and Updates on Antimicrobial Agents from Natural Products**. *Biomed.Res.Int.* 2019, **2019:**7079864.

4. Reygaert WC: **Green Tea Catechins: Their Use in Treating and Preventing Infectious Diseases**. *Biomed.Res.Int.* 2018, **2018:**9105261.

5. Furushima D, Ide K, Yamada H: **Effect of Tea Catechins on Influenza Infection and the Common Cold with a Focus on Epidemiological/Clinical Studies**. *Molecules.* 2018, **23**.

6. Nanri A, Nakamoto K, Sakamoto N, Imai T, Mizoue T: **Green tea consumption and influenza infection among Japanese employees**. *Eur.J.Clin.Nutr.* 2020.

7. Wu C, Liu Y, Yang Y, Zhang P, Zhong W, Wang Y, Wang Q, Xu Y, Li M, Li X, Zheng M, Chen L, Li H: **Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods**. *Acta Pharm.Sin.B* 2020.

8. Jang M, Park YI, Cha YE, Park R, Namkoong S, Lee JI, Park J: **Tea Polyphenols EGCG and Theaflavin Inhibit the Activity of SARS-CoV-2 3CL-Protease In Vitro**. *Evid.Based.Complement Alternat.Med.* 2020, **2020:**5630838.

9. Momose Y, Maeda-Yamamoto M, Nabetani H: **Systematic review of green tea epigallocatechin gallate in reducing low-density lipoprotein cholesterol levels of humans**. *Int.J.Food Sci.Nutr.* 2016, **67:**606-613.

10. Xu R, Yang K, Li S, Dai M, Chen G: **Effect of green tea consumption on blood lipids: a systematic review and meta-analysis of randomized controlled trials**. *Nutr.J.* 2020, **19:**48.

11. Khan N, Mukhtar H: **Tea and health: studies in humans**. *Curr.Pharm.Des* 2013, **19:**6141-6147.

12. Lin Y, Shi D, Su B, Wei J, GÄƒman MA, Sedanur MM, Borges do Nascimento IJ, Guimaraes NS: **The effect of green tea supplementation on obesity: A systematic review and dose-response meta-analysis of randomized controlled trials**. *Phytother.Res.* 2020.

13. Abe SK, Inoue M: **Green tea and cancer and cardiometabolic diseases: a review of the current epidemiological evidence**. *Eur.J.Clin.Nutr.* 2020.

medRxiv preprint doi: https://doi.org/10.1101/2020.10.23.20218479; this version posted December 11, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

14. Menegazzi M, Campagnari R, Bertoldi M, Crupi R, Di PR, Cuzzocrea S: **Protective Effect of Epigallocatechin-3-Gallate (EGCG) in Diseases with Uncontrolled Immune Activation: Could Such a Scenario Be Helpful to Counteract COVID-19?** *Int.J.Mol.Sci*. 2020, **21**.

15. Tang Y, Liu J, Zhang D, Xu Z, Ji J, Wen C: **Cytokine Storm in COVID-19: The Current Evidence and Treatment Strategies**. *Front Immunol*. 2020, **11:**1708.

16. Wessels I, Rolles B, Rink L: **The Potential Impact of Zinc Supplementation on COVID-19 Pathogenesis**. *Front Immunol.* 2020, **11:**1712.

17. Alschuler L, Weil A, Horwitz R, Stamets P, Chiasson AM, Crocker R, Maizes V: **Integrative considerations during the COVID-19 pandemic**. *Explore.(NY)* 2020, **16:**354-356.

18. **Coffee, tea, mate, methylxanthines and methylglyoxal. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Lyon, 27 February to 6 March 1990**. *IARC Monogr Eval.Carcinog.Risks Hum.* 1991, **51:**1-513.

19. Yukio Kosugi: **Green tea consumption**. *World Green Tea Association Available at: http://www o-cha net/english/teacha/distribution/greentea3 html*. 2020.

20. Tea Research and Extension Station: **Taiwan Tea Industry**. *https://www.tres.gov.tw/en/ws.php?id=1000* 2020.

21. INTERGOVERNMENTAL GROUP ON TEA TWENTY-THIRD SESSION: **Emerging Trends in Tea Consumption: Informing a Generic Promotion Process**. *http://www.fao.org/economic/est/est-commodities/tea/tea-meetings/tea23/en/* 2018.

22. INTERGOVERNMENTAL GROUP ON TEA: **CURRENT MARKET SITUATION AND MEDIUM TERM OUTLOOK**. *http://www.fao.org/economic/est/est-commodities/tea/tea-meetings/tea23/en/* 2018.

23. **Commodity Trade Statistics Database**|: United Nations Statistics Division. *Available at http://data.un.org/Data.aspx?d=ComTrade&f=_l1Code%3A10* 2016.

24. Worldometers info.: **Coronavirus update**. *Available at: https://www.worldometers.info/coronavirus/*.

25. Urashima M, Otani K, Hasegawa Y, Akutsu T: **BCG Vaccination and Mortality of COVID-19 across 173 Countries: An Ecological Study**. *Int.J.Environ.Res.Public Health* 2020, **17**.

26. Klinger D, Blass I, Rappoport N, Linial M: **Significantly Improved COVID-19 Outcomes in Countries with Higher BCG Vaccination Coverage: A Multivariable Analysis**. *Vaccines.(Basel)* 2020, **8**.

27. Madan M, Pahuja S, Mohan A, Pandey RM, Madan K, Hadda V, Tiwari P, Guleria R, Mittal S: **TB infection and BCG vaccination: are we protected from COVID-19?** *Public Health* 2020, **185:**91-92.

medRxiv preprint doi: https://doi.org/10.1101/2020.10.23.20218479; this version posted December 11, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

28. World Bank: **Population density (people per sq. km of land area).** *https://data.worldbank.org/indicator/EN.POP.DNST.* 2019.

29. World Bank: **Population ages 65 and above (% of total population)** . *https://data.worldbank.org/indicator/SP.POP.65UP.TO.ZS* 2019.

30. World Bank: **Urban population (% of total population).** *https://data.worldbank.org/indicator/SP.URB.TOTL.IN.ZS.*.

31. United Nations Development Program. **Human Development Reports.** *http://hdr.undp.org/en/content/2019-human-development-index-ranking* 2019.
32. Escobar LE, Molina-Cruz A, Barillas-Mury C: **BCG vaccine protection from severe coronavirus disease 2019 (COVID-19)**. *Proc.Natl.Acad.Sci.U.S.A* 2020, **117:**17720-17726.

33. Tukey J.: ***Exploratory data analysis***. Reading, Mass: Addison-Wesley Pub. Co.; 1977.

34. Aguiar M, Stollenwerk N: **Condition-specific mortality risk can explain differences in COVID-19 case fatality ratios around the globe**. *Public Health* 2020, **188:**18-20.

35. Hajian TK: **Methodological issues of confounding in analytical epidemiologic studies**. *Caspian.J.Intern.Med.* 2012, **3:**488-495.

36. Furushima D, Nishimura T, Takuma N, Iketani R, Mizuno T, Matsui Y, Yamaguchi T, Nakashima Y, Yamamoto S, Hibi M, Yamada H: **Prevention of Acute Upper Respiratory Infections by Consumption of Catechins in Healthcare Workers: A Randomized, Placebo-Controlled Trial**. *Nutrients.* 2019, **12**.

medRxiv preprint doi: https://doi.org/10.1101/2020.10.23.20218479; this version posted December 11, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Supplementary materials

Supplementary **Table S1**

A - values obtained in multiple regression model with Log(cases/million)$_{6\text{-month}}$ as dependent variable and four independent variables.

Regression Coefficient

	Estimate	SE	t(cal)		P(T<=t(cal))	Lower 95%	Upper 95%	VIF (Variance Inflation Factor)
b0	2.02914	0.216249	9.383368	*** (P<=0.001)	2.42E-15	1.600056	2.458224	
b1:X1	-0.00066	0.000269	-2.45775	* (P<=0.05)	0.01571916	-0.00119	-0.00013	1.005797
b2:X2	-7.67E-05	6.23E-05	-1.23027	N.S. (P>0.05)	0.22151029	-0.0002	4.70E-05	1.071775
b3:X3	-0.00279	0.01032	-0.27017	N.S. (P>0.05)	0.78758909	-0.02327	0.01769	1.342564
b4:X4	0.020264	0.003639	5.568247	*** (P<=0.001)	2.21E-07	0.013043	0.027485	1.418162

Standard Regression Coefficient

	Estimate	SE
b1:X1	-0.20397	0.082991
b2:X2	-0.1054	0.08567
b3:X3	-0.02591	0.095884
b4:X4	0.54873	0.098546

	Legend
X1	green tea consumption
X2	pop. density/sq km
X3	%pop. aged above 65
X4	Urban population % of total
Y	Log(cases/million)$_{6\text{-month}}$

B - values obtained in multiple regression model with Log(death/million)$_{6\text{-month}}$ as dependent variable and four independent variables

Regression Coefficient

	Estimate	SE	t(cal)		P(T<=t(cal))	Lower 95%	Upper 95%	VIF (Variance Inflation Factor)
b0	0.630148	0.247711	2.543886	* (P<=0.05)	0.012542	0.138511	1.121785	
b1:X1	-0.00071	0.000305	-2.33584	* (P<=0.05)	0.021559	-0.00132	-0.00011	1.006898
b2:X2	-0.0002	6.96E-05	-2.94345	** (P<=0.01)	0.004061	-0.00034	-6.67E-05	1.074656
b3:X3	0.016655	0.011569	1.439702	N.S. (P>0.05)	0.153171	-0.00631	0.039616	1.341715
b4:X4	0.015295	0.004148	3.687101	*** (P<=0.001)	0.000374	0.007062	0.023528	1.424638

Standard Regression Coefficient

	Estimate	SE
b1:X1	-0.2013	0.086179
b2:X2	-0.26206	0.089031
b3:X3	0.143222	0.099481
b4:X4	0.37796	0.102509

	Legend
X1	green tea consumption
X2	pop. density/sq kilom
X3	%pop. Aged above 65
X4	Urban population % of total
Y	Log(deaths/million)$_{6\text{-month}}$

medRxiv preprint doi: https://doi.org/10.1101/2020.10.23.20218479; this version posted December 11, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Supplementary **Table S2**

A - values obtained in multiple regression model with Log(cases/million)$_{6\text{-month}}$ as dependent variable and five independent variables.

Regression Coefficient

	Estimate	SE	t(cal)		P(T<=t(cal))	Lower 95%	Upper 95%	VIF (Variance Inflation Factor)
b0	1.145214	0.373509	3.066099	** (P<=0.01)	0.00280274	0.403999	1.88643	
b1:X1	-0.00066	0.000259	-2.55675	* (P<=0.05)	0.01209993	-0.00118	-0.00015	1.005814
b2:X2	-8.19E-05	6.02E-05	-1.35941	N.S. (P>0.05)	0.17713749	-0.0002	3.77E-05	1.072751
b3:X3	-0.0304	0.013889	-2.18871	* (P<=0.05)	0.03099345	-0.05796	-0.00284	2.607088
b4:X4	0.010963	0.004793	2.287384	* (P<=0.05)	0.02432362	0.001452	0.020474	2.637239
b5:X5	2.400156	0.840853	2.854431	** (P<=0.01)	0.00526182	0.731511	4.0688	4.758361

Standard Regression Coefficient

	Estimate	SE		Legend
b1:X1	-0.20492	0.080149	X1	green tea consumption
b2:X2	-0.11252	0.082773	X2	pop. density/sq km
b3:X3	-0.28243	0.129038	X3	%pop. aged above 65
b4:X4	0.296861	0.129782	X4	Urban population % of total
b5:X5	0.497609	0.174328	X5	Human Development Index (HDI)
			Y	Log(cases/million)$_{6\text{-month}}$

B - values obtained in multiple regression model with Log(death/million)$_{6\text{-month}}$ as dependent variable and five independent variables

Regression Coefficient

	Estimate	SE	t(cal)		P(T<=t(cal))	Lower 95%	Upper 95%	VIF (Variance Inflation Factor)
b0	0.105057	0.430313	0.244141	N.S. (P>0.05)	0.807643	-0.74911	0.959222	
b1:X1	-0.00071	0.000303	-2.34253	* (P<=0.05)	0.02121881	-0.00131	-0.00011	1.006926
b2:X2	-0.00021	6.92E-05	-3.00509	** (P<=0.01)	0.00338719	-0.00035	-7.06E-05	1.075623
b3:X3	-3.92E-05	0.016065	-0.00244	N.S. (P>0.05)	0.9980564	-0.03193	0.03185	2.619868
b4:X4	0.009634	0.00561	1.717219	N.S. (P>0.05)	0.08916359	-0.0015	0.020773	2.638329
b5:X5	1.443456	0.970221	1.48776	N.S. (P>0.05)	0.14009154	-0.48242	3.369329	4.773061

Standard Regression Coefficient

	Estimate	SE		Legend
b1:X1	-0.20063	0.085646	X1	green tea consumption
b2:X2	-0.26601	0.088519	X2	pop. density/sq km
b3:X3	-0.00034	0.138149	X3	%pop. aged above 65
b4:X4	0.238067	0.138635	X4	Urban population % of total
b5:X5	0.277421	0.186469	X5	Human Development Index (HDI)
			Y	Log(deaths/million)$_{6\text{-month}}$

medRxiv preprint doi: https://doi.org/10.1101/2020.10.23.20218479; this version posted December 11, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.